MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 187 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

  • (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 M{DXU2N6fG:2b4jpZ{BCe3OjeR?= M2LtSFMh|ryP NFHofYY4OiCq NYrsNYM4TE2VTx?= M{nTW2lvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w NGDaTnIzODV5MUC2PS=>
A431 MXTLbY5ie2ViQYPzZZk> Mn\OOUDPxE1? M3e5W|UhcA>? NIXrOGNFVVOR NWrpVpZFW3WycILld5NmeyC2aHWgd4lodmGuaX7nJI9nKEGtdDDhcoQhTXKt MXWyNFU4OTB4OR?=
HepG2 NUnNbphQS3m2b4TvfIlkKEG|c3H5 MlL5NVAh|ryP NFX6SoMzPCCq MVvEUXNQ MkPyV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni MUKyNVIxPTl{NR?=
Sk-Hep1 NUfNc4h6S3m2b4TvfIlkKEG|c3H5 M2DKdFExKM7:TR?= NFjY[ZQzPCCq NX6zcVBPTE2VTx?= M1fpbHNmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> NYqySodrOjF{MEW5NlU>
OCUT1 cells harbored PIK3CA (H1047R+/+) M4nReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7iU5ZLOyEQvF2= NX3oT3gyPSCm NEGwPYFFVVOR MV7JR|UxRTBwMUSg{txO MVqyNVI5QTJ4Nx?=
K1 cells harbored PIK3CA (E542K+/+) NGXvPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jX[lMh|ryP MmWwOUBl MXnEUXNQ Mlj5TWM2OD1yLkWyJO69VQ>? NXzUOmJROjF{OEmyOlc>
FTC133 cells harbored PTEN (allele deletion and R130+) NGj0O|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHyVJQ{KM7:TR?= NEjMNow2KGR? NHjxcFlFVVOR MXHJR|UxRTBwMUig{txO Ml3LNlEzQDl{Nke=
C643 cells harbored HRAS (G13R+/−) NHm3UXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jYfFMh|ryP NIj0cJQ2KGR? MnnOSG1UVw>? NVr2RXVnUUN3ME2wMlI4KM7:TR?= NY\t[2hIOjF{OEmyOlc>
Hth7 cells harbored NRAS (Q61R+/−) NILFfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzjN{DPxE1? MUC1JIQ> NXzlbpZwTE2VTx?= MkLoTWM2OD12LkWg{txO MUeyNVI5QTJ4Nx?=
TPC1 cells harbored RET/PTC1 rearrangement NYH0PWZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyzJO69VQ>? NWqzPVBVPSCm NH\oXWxFVVOR NYLlZ4JvUUN3ME2wMlU6KM7:TR?= NYK4cINKOjF{OEmyOlc>
Hth74 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TFdVMh|ryP MWG1JIQ> MYTEUXNQ M3HOSmlEPTB;Mj6xPUDPxE1? M2jORVIyOjh7Mk[3
KAT18 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvGb41WOyEQvF2= MWe1JIQ> MVfEUXNQ NF7CVWtKSzVyPUSuOlIh|ryP NF\0d3YzOTJ6OUK2Oy=>
SW1736 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoThNVAxKM7:TR?= MW[1JIQ> NIDQTFZFVVOR NITyNYNKSzVyPUS3MlU3KM7:TR?= Mm\xNlEzQDl{Nke=
WRO MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;kWnRLOTByMDFOwG0> NGrEbok2KGR? NWGwXmtUTE2VTx?= M3fkPWlEPTB-MUCwNEDPxE1? MlfLNlEzQDl{Nke=
TAD2 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;Y[ncyODByIN88US=> MlLaOUBl MXXEUXNQ MVfJR|UxRjFyMECg{txO MXSyNVI5QTJ4Nx?=
LN229 MUPBdI9xfG:|aYOgRZN{[Xl? NF:zXVcxNjVizszN MlLWOlAhcA>? MYLEUXNQ NUP4RmE2SXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= MnjQNlIxPTd7MUS=
T98G MlvGRZBweHSxc3nzJGF{e2G7 MmLiNE42KM7:TR?= NUjhWGg5PjBiaB?= MmLmSG1UVw>? NFnCOo5CfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= NF\OTnQzOjB3N{mxOC=>
HC11 M{XBfWZ2dmO2aX;uJGF{e2G7 NYXvfYpoOTBizszN M2TxS|I1KGh? MXrEUXNQ NEDB[lNKdmirYnn0d{DPui2lYYPlbY4h[W6mIFHEVnAhe3mwdHjld4l{ MWqyNlQzPjZ{MR?=
MOLT-4 Ml;xR5l1d3SxeHnjJGF{e2G7 NEfvZVIyOCEQvF2= M4XJeVQ5KGh? M1LMe2ROW09? NGL4ZmhKSzVyPUGuO-KBkc7:TR?= NYrFTVRXOjJ4MUSyOFM>
CEM-R MVHDfZRwfG:6aXOgRZN{[Xl? NGmxdm8yOCEQvF2= NE\VN401QCCq M3rCO2ROW09? M1T2dmlEPTB;Mz6z5qCK|ryP NXizO4NiOjJ4MUSyOFM>
CEM-S MWjDfZRwfG:6aXOgRZN{[Xl? MlS1NVAh|ryP NIf6TYw1QCCq M{DJV2ROW09? MYXJR|UxRTVwMfMAje69VQ>? NWnNNmxsOjJ4MUSyOFM>
MOLT-4 NV2xU5BjTnWwY4Tpc44hSXO|YYm= MlPxNVAh|ryP M2PsOFI1KGh? NIPITpVFVVOR M3PnN2Jtd2OtczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2Vib3[geIhmKGOnbHygZ5lkdGV? NWTBUW05OjJ4MUSyOFM>
MOLT-4 Mk\rSpVv[3Srb36gRZN{[Xl? Mn3aOQKBkc7:TR?= MmDWOEBp NWq3dmRPTE2VTx?= NYjjN5k4UW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|NCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ MX2yNlYyPDJ2Mx?=
CEM-R MWTGeY5kfGmxbjDBd5NigQ>? NEnVWWg16oDLzszN MV[0JIg> NIXuXGpFVVOR NX22S4RJUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|RCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ MWWyNlYyPDJ2Mx?=
CEM-S NYfGWo1MTnWwY4Tpc44hSXO|YYm= M2m5O|TjiIoQvF2= M4jlR|QhcA>? NX2wdYhuTE2VTx?= NFfW[VJKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOWEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? MYqyNlYyPDJ2Mx?=
HepG2 cell MYHLbY5ie2ViQYPzZZk> NEDtbHIzOCEQvF2= NWP3R3BjOjRiaB?= MYjEUXNQ MmHHSI94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? NHXrRoEzOzd7N{OxPS=>
HepG2 cell NVPrSZRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf1N|Ah|ryP M1vmTVI1KGh? MVPEUXNQ MnvqTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MUGyN|c6PzNzOR?=
HepG2 cell MmTSRZBweHSxc3nzJGF{e2G7 NX;ofFIyOjBizszN MoC1NlQhcA>? MUPEUXNQ NEnEb5pKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MkXxNlM4QTd|MUm=
GEO Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrlT5c2ODBibl2= MWi3NkBp NEWwOFlFVVOR MV;Jcohq[mm2czDj[YxtKGe{b4f0bC=> M{nMSFI1PThzMkOx
CNE-1 NHz6[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOxNEDPxE1? MXi5OkBp MorBSG1UVw>? NWm5PZVWUUN3ME2yMlk3KM7:TR?= M3P1PVI2OzN4OUK1
CNE-2 NF3K[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm0NVAh|ryP M{nrPFk3KGh? MnfNSG1UVw>? Mk\qTWM2OD12LkWzJO69VQ>? M2rrTlI2OzN4OUK1
HONE-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXxXnIyOCEQvF2= MVK5OkBp M13kfGROW09? NX3CVYdKUUN3ME2zMlM4KM7:TR?= MYGyOVM{Pjl{NR?=
SUNE-1 NEW2OJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nCflExKM7:TR?= M3iwNlk3KGh? MYDEUXNQ NVTLW2RRUUN3ME2wMlUzKM7:TR?= MnP4NlU{OzZ7MkW=
CNE-2 MXjGeY5kfGmxbjDBd5NigQ>? NUTpOmpSOTBizszN NVLxR4RmPDhiaB?= MlXWSG1UVw>? MWjJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy MmXDNlU{OzZ7MkW=
HONE-1 NFe4UndHfW6ldHnvckBCe3OjeR?= Mk\MNVAh|ryP M{fJdVQ5KGh? NHTJSHNFVVOR MWjJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy M{\UbVI2OzN4OUK1
NEC8 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPP[YRNUUN3ME2wMlA6PjVzIN88US=> NYPXRVNLW0GQR1XS
P12-ICHIKAWA Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDKTWM2OD1yLkGxOlIh|ryP NEjjWlBUSU6JRWK=
MDA-MB-175-VII MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrsNWRKSzVyPUCuNVM4OzhizszN MWrTRW5ITVJ?
AsPC-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMkKxNlIh|ryP MmS2V2FPT0WU
T47D M{e1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMkiyOUDPxE1? NF;uNYpUSU6JRWK=
HH NXfrN4FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXu[mNKSzVyPUCuN|AzQDNizszN NHLobYdUSU6JRWK=
MOLT-16 NEHR[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwM{CzNkDPxE1? MkT2V2FPT0WU
ES5 NXjJeVliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjtdYtJUUN3ME2wMlM1PDV3IN88US=> M{\kT3NCVkeHUh?=
RS4-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO3cFA3UUN3ME2wMlM1PjFizszN NVXyVGQ2W0GQR1XS
KARPAS-45 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rsSGlEPTB;MD6zO|MzOSEQvF2= MY\TRW5ITVJ?
NCI-H720 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PrTWlEPTB;MD6zO|Y4QSEQvF2= MoXKV2FPT0WU
H9 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHW[XNZUUN3ME2wMlM5QDh|IN88US=> NHOwN5lUSU6JRWK=
EFM-19 M3GwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELLbGdKSzVyPUCuOFQxOSEQvF2= NX\DWlV5W0GQR1XS
SBC-1 M{\k[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M362W2lEPTB;MD60OFA{PSEQvF2= NFexO2FUSU6JRWK=
A4-Fuk MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\kSZFQUUN3ME2wMlQ3QDZ6IN88US=> NVzMPVRNW0GQR1XS
NCI-H1563 MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LLZ2lEPTB;MD60PFE5QSEQvF2= NU\QR2NGW0GQR1XS
HCC1419 NH\PO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPETWM2OD1yLkS4PFkzKM7:TR?= Mke4V2FPT0WU
H-EMC-SS M4XaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvzWXJKSzVyPUCuOFk6OzlizszN MYHTRW5ITVJ?
BHT-101 NUX2W2c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDtTWM2OD1yLkWyPVYyKM7:TR?= NXTpWHRmW0GQR1XS
IGROV-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX3bGYzUUN3ME2wMlU2OjR7IN88US=> NEC1d|hUSU6JRWK=
HGC-27 NF7NWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7tVodKSzVyPUCuOVY4QDNizszN MofYV2FPT0WU
MDA-MB-361 NWT6Uog4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm0TWM2OD1yLkW3O|YyKM7:TR?= M3jte3NCVkeHUh?=
KE-37 MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vqb2lEPTB;MD61PFI3KM7:TR?= NVrxXphYW0GQR1XS
HCC70 NVnHS|F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwNUm4Nlch|ryP MmDVV2FPT0WU
LNCaP-Clone-FGC M3zOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X1eWlEPTB;MD62NVA1QCEQvF2= MnXzV2FPT0WU
HAL-01 NXrvcYxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nrUWlEPTB;MD62NlE{KM7:TR?= MoLlV2FPT0WU
HT NH[zRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDlT5RlUUN3ME2wMlY{OjN7IN88US=> NGr2SIlUSU6JRWK=
MDA-MB-415 MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXHcXZKSzVyPUCuOlM3OjZizszN NYKzWFNyW0GQR1XS
NOS-1 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwNkO3NlMh|ryP Ml3DV2FPT0WU
DU-145 M2KzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDN[lJKSzVyPUCuOlQ4PDVizszN MlPSV2FPT0WU
OCUB-M MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;6TGlEPTB;MD63NFk3PiEQvF2= NV\jcmRtW0GQR1XS
VA-ES-BJ MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwN{OwNlUh|ryP M3v2SXNCVkeHUh?=
J-RT3-T3-5 NYK4NIlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\WdGlEPTB;MD63OFQxOyEQvF2= NWrmRmNDW0GQR1XS
MOLT-4 NXjvbY9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP2bpA5UUN3ME2wMlgxPTh{IN88US=> NE\S[2RUSU6JRWK=
NB7 NHH1V5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHtcWdKSzVyPUCuPFI1OTFizszN M4C5OHNCVkeHUh?=
L-363 NYDJ[5hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInieZhKSzVyPUCuPFM1PDJizszN NI\lb|hUSU6JRWK=
NKM-1 NW\QWJpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXXTWM2OD1yLki2NlU{KM7:TR?= M1nCV3NCVkeHUh?=
HOP-92 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq4fYIzUUN3ME2wMlg4OjJ|IN88US=> MmXjV2FPT0WU
OAW-42 NVfr[YxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnlT5FKSzVyPUCuPFg4OiEQvF2= MXfTRW5ITVJ?
HuO9 NWLSdFFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrRToFKSzVyPUCuPVI4PTFizszN NFfYPXRUSU6JRWK=
MFE-280 Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwOU[0OlUh|ryP Mn\rV2FPT0WU
EM-2 NUjtbYJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HuVWlEPTB;MD65O|k{QSEQvF2= MoPoV2FPT0WU
NCI-H520 NWfOOohvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TM[WlEPTB;MD65PFU6OiEQvF2= M4PlT3NCVkeHUh?=
LB2241-RCC MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwOUm3N|Qh|ryP NGfQeXlUSU6JRWK=
SK-NEP-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjlXm5JUUN3ME2xMlE1PDh3IN88US=> M1nTUXNCVkeHUh?=
LXF-289 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH3SG1KSzVyPUGuNVcyPTZizszN M4S4c3NCVkeHUh?=
EPLC-272H MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwMUeyOVYh|ryP M1HHfnNCVkeHUh?=
COLO-684 NV3xfYRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1npXmlEPTB;MT6yN|czPSEQvF2= NV\hWpVkW0GQR1XS
ES1 M4XxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrxTWM2OD1zLkK0NFY2KM7:TR?= MYPTRW5ITVJ?
DOHH-2 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW3UmR5UUN3ME2xMlI5OjB|IN88US=> M2LtZnNCVkeHUh?=
CTB-1 M1j2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXMTWM2OD1zLkK4PVkh|ryP MXrTRW5ITVJ?
G-401 M3[3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW1cYNZUUN3ME2xMlI6Pzl3IN88US=> MUXTRW5ITVJ?
LoVo M1Pld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjYVHZKSzVyPUGuN|I2OzRizszN NXyxS5FDW0GQR1XS
Ramos-2G6-4C10 NGXJNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwM{O3NFEh|ryP NF7iVJBUSU6JRWK=
MFM-223 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jld2lEPTB;MT6zOFQ3OSEQvF2= MV3TRW5ITVJ?
PA-1 M3LPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\DZmlEPTB;MT6zOVI3PSEQvF2= M2i4PHNCVkeHUh?=
697 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jGWGlEPTB;MT6zO|YyPiEQvF2= M4rYR3NCVkeHUh?=
QIMR-WIL M1\pS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG5co4yUUN3ME2xMlQ6OTF4IN88US=> MV;TRW5ITVJ?
HOS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLCXGlKSzVyPUGuOFk2PThizszN NH7Y[5dUSU6JRWK=
DMS-273 M2HKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfuRmlKSzVyPUGuOVE6PTlizszN NXz1bYd6W0GQR1XS
ME-180 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj4S2dKSzVyPUGuOVY5QTFizszN MkTHV2FPT0WU
HCC2218 NWSzdIVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwNkiyNlUh|ryP MVXTRW5ITVJ?
CAL-54 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nCRWlEPTB;MT63NVI1OiEQvF2= M3rodHNCVkeHUh?=
OMC-1 NUjkTGpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vlSGlEPTB;MT63OFY4PyEQvF2= MlTOV2FPT0WU
COR-L105 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\vTIhKSzVyPUGuO|k4OzdizszN M3XVcnNCVkeHUh?=
BV-173 NXfZNWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnUUZlrUUN3ME2xMlgyODd2IN88US=> M1;LR3NCVkeHUh?=
RKO M{W4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17PN2lEPTB;MT64O|ExOSEQvF2= NWDKXnpWW0GQR1XS
SNU-387 NHfUTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jDdmlEPTB;MT64PFQxPiEQvF2= Mn;GV2FPT0WU
SW1088 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrVPZk1UUN3ME2xMlk1PjB4IN88US=> MX3TRW5ITVJ?
Hs-578-T NHzwVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwMUG0N|Mh|ryP NEnzNpNUSU6JRWK=
OC-314 M2\IS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTPSlFKSzVyPUKuNVUxQDZizszN MlrDV2FPT0WU
RMG-I NY\ET5dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLaTWM2OD1{LkG2N|k5KM7:TR?= NU[0UId7W0GQR1XS
NCI-H1395 M2XwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHMTWM2OD1{LkG4NFkyKM7:TR?= NHfBUYJUSU6JRWK=
GAMG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi5NllKUUN3ME2yMlI{QDR3IN88US=> M13Zc3NCVkeHUh?=
LB1047-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T4XWlEPTB;Mj6yOFMyPyEQvF2= MmS3V2FPT0WU
MN-60 NYnweXN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PsVmlEPTB;Mj6yPVkzOyEQvF2= M131NXNCVkeHUh?=
OAW-28 NUPWWllbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7VVFMxUUN3ME2yMlI6QTVzIN88US=> MWHTRW5ITVJ?
NCI-H2228 M33JW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DMd2lEPTB;Mj6zNVU2OiEQvF2= MVXTRW5ITVJ?
ABC-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;1RWlEPTB;Mj6zN|I2OyEQvF2= MUHTRW5ITVJ?
LS-513 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHufVVKSzVyPUKuN|M1QDRizszN NFfZOmRUSU6JRWK=
KS-1 NFPzTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ewbGlEPTB;Mj6zPFE6OSEQvF2= NYnjNYxTW0GQR1XS
NB69 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwM{i5PFMh|ryP MWfTRW5ITVJ?
VM-CUB-1 M3vkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnlSHZKSzVyPUKuN|kxQDNizszN MU\TRW5ITVJ?
D-423MG MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;ZUFhKSzVyPUKuOFExPDRizszN Mn3sV2FPT0WU
EW-18 NYrWbGhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJwNEG5N|kh|ryP M1njcnNCVkeHUh?=
YH-13 M1izV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfKV|BKSzVyPUKuOFYyPTNizszN NWGxZmZWW0GQR1XS
T-24 M3\uVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqzRopEUUN3ME2yMlQ4QDhzIN88US=> NGf3dGxUSU6JRWK=
ES8 NX7BPZV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7RcIZZUUN3ME2yMlQ6Ojh5IN88US=> NHnLepRUSU6JRWK=
ES3 NWHwPI85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7PdVROUUN3ME2yMlQ6PzV7IN88US=> MXfTRW5ITVJ?
RXF393 NGO2SFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuzTWM2OD1{Lk[wOFg4KM7:TR?= MnXyV2FPT0WU
RPMI-8226 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwNkK5OVMh|ryP MoPEV2FPT0WU
AGS M17SV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJwN{KxN|ch|ryP NIPKZ41USU6JRWK=
HCC1395 NUHD[YJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv1SpJXUUN3ME2yMlc2OTh5IN88US=> MlLiV2FPT0WU
MV-4-11 NEnrS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwN{WyOlYh|ryP NFrsdZpUSU6JRWK=
A204 NVj4OnVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwOEO4O|Ih|ryP MmXPV2FPT0WU
MCF7 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJwOE[xNVch|ryP NWHlflJPW0GQR1XS
SNU-423 M1OzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX1SIJKSzVyPUKuPFkzPDJizszN MVrTRW5ITVJ?
NCI-H1048 NWPHT4dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwOU[4OlUh|ryP NXXGW3A1W0GQR1XS
GR-ST NHrlNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nhcWlEPTB;Mz6wOFYyOSEQvF2= NYjQSWhDW0GQR1XS
EoL-1- MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNwMEewOVgh|ryP M2e1T3NCVkeHUh?=
HuH-7 NWexOolPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW4TWM2OD1|LkC5OFY1KM7:TR?= MYnTRW5ITVJ?
OS-RC-2 NVTsOIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrqc5ZpUUN3ME2zMlEyOTlizszN NH7yXYhUSU6JRWK=
EW-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\hTWM2OD1|LkG5OVI6KM7:TR?= M1jpRXNCVkeHUh?=
NCI-H747 NGm1NXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S5bGlEPTB;Mz6yNFY6PCEQvF2= NGG3UplUSU6JRWK=
EW-16 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNwMkG4O|kh|ryP M2GzXnNCVkeHUh?=
DOK MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrHVlZKSzVyPUOuNlI5PTlizszN NWrqVoJwW0GQR1XS
HCC2157 NFezcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNwM{ixO|kh|ryP NF3HdGhUSU6JRWK=
OVCAR-3 NUXmUVRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPpfVVKSzVyPUOuOFA4QDZizszN M1rXOnNCVkeHUh?=
NCI-H1623 Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXFTWM2OD1|LkSxNlI1KM7:TR?= NY\6RVN1W0GQR1XS
H4 M2njU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNwNEW2NlYh|ryP M3zFO3NCVkeHUh?=
SW1710 NVXTVoxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jQemlEPTB;Mz60OlY4QCEQvF2= Mn[5V2FPT0WU
RT-112 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTNwNUKzPFgh|ryP MUfTRW5ITVJ?
DMS-114 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjuWmFKSzVyPUOuOlIzPzhizszN M1i2ZnNCVkeHUh?=
AN3-CA MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PrT2lEPTB;Mz62NlQ2PiEQvF2= NFzmXXJUSU6JRWK=
KNS-62 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXiNXJ5UUN3ME2zMlY{OzN6IN88US=> M2jEfHNCVkeHUh?=
SJRH30 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNwNkmxNlIh|ryP Ml6wV2FPT0WU
G-402 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nHTWlEPTB;Mz63NFcyOSEQvF2= M{PFc3NCVkeHUh?=
MHH-PREB-1 NY\HRmllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D6SGlEPTB;Mz63NlA{QCEQvF2= MYTTRW5ITVJ?
P30-OHK NVm1eoJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT5PXhpUUN3ME2zMlgxQTd4IN88US=> Mm\KV2FPT0WU
RVH-421 M3fuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGezdFdKSzVyPUOuPFE4QDhizszN MYTTRW5ITVJ?
LU-134-A M3zw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj4bmNFUUN3ME2zMlg5PDJ6IN88US=> MljJV2FPT0WU
ECC10 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTyVldkUUN3ME2zMlk{PjJ{IN88US=> NWnET3k{W0GQR1XS
TGW NGnvVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTlW|NkUUN3ME20MlAzOzB3IN88US=> MWXTRW5ITVJ?
MLMA NXT6OWM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljXTWM2OD12LkCyPVY3KM7:TR?= MoTQV2FPT0WU
SCC-25 M4LhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TBUmlEPTB;ND6wOlU3PiEQvF2= MlrKV2FPT0WU
TYK-nu M174VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTRwMEm1N|Qh|ryP NFTsSJdUSU6JRWK=
LAMA-84 NVrQb2V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnTb3NuUUN3ME20MlE1OTlzIN88US=> M1nQXXNCVkeHUh?=
Calu-3 NHvRZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTRwMkS0NVYh|ryP MWHTRW5ITVJ?
NCI-H460 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvyOZhKSzVyPUSuNlY1PDNizszN MVnTRW5ITVJ?
EGI-1 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXpcGNbUUN3ME20MlM4Pzd6IN88US=> NEGxRolUSU6JRWK=
NCI-H292 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwM{ixOFYh|ryP NIjKcY1USU6JRWK=
HCE-T MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\x[mlEPTB;ND60NVU4QSEQvF2= MUnTRW5ITVJ?
EW-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTRwNEG4N|gh|ryP MnvpV2FPT0WU
ATN-1 NGjFWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvQfphKSzVyPUSuOFQ{ODRizszN MWHTRW5ITVJ?
NB5 NUDENm8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13nbWlEPTB;ND61N|Y6PyEQvF2= MYDTRW5ITVJ?
KLE MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3vTWM2OD12LkewNVk5KM7:TR?= M1nIbHNCVkeHUh?=
CAL-39 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO5Z4ZuUUN3ME20MlczOTR4IN88US=> M1P3NXNCVkeHUh?=
TI-73 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHqflZKSzVyPUSuPFA3ODlizszN MUnTRW5ITVJ?
HO-1-N-1 NF;YbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG0TWM2OD12Lkm0NkDPxE1? NV\r[pp1W0GQR1XS
786-0 NFnpc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRwOUS2O|Mh|ryP NFvzdWFUSU6JRWK=
SK-N-DZ Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrVOVdRUUN3ME20Mlk3OTR{IN88US=> MoPMV2FPT0WU
NCI-H446 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTVwMkCwNFkh|ryP Ml3DV2FPT0WU
ETK-1 NGLkRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfXTWM2OD13LkKxNVY2KM7:TR?= NGCwepBUSU6JRWK=
BT-20 NVXOUpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i4PGlEPTB;NT6yNVM2OyEQvF2= MkniV2FPT0WU
MEL-HO M{X1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWwPIlmUUN3ME21MlM4OzN4IN88US=> MlvRV2FPT0WU
CAL-27 MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDYWHFtUUN3ME21MlQ3OzN7IN88US=> M2W0OHNCVkeHUh?=
SW872 M{TnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TlOmlEPTB;NT61PVQzQCEQvF2= NFPYWY1USU6JRWK=
RPMI-2650 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHvTWM2OD13Lk[2NVk6KM7:TR?= MYrTRW5ITVJ?
PFSK-1 NXnIO2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T2dWlEPTB;NT63Nlc{OiEQvF2= NFzSWFRUSU6JRWK=
SF295 M2\keGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vYbWlEPTB;NT64NFY{OyEQvF2= M3[4UnNCVkeHUh?=
Becker Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrCTWM2OD13Lki2OFczKM7:TR?= Ml2zV2FPT0WU
Saos-2 NHnBZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHyTWM2OD13Lki2OVMh|ryP MnH6V2FPT0WU
SK-OV-3 NIG3SnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITkUY1KSzVyPUWuPVk5OTZizszN M3n2ZnNCVkeHUh?=
VMRC-RCZ M1n0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTZwMEi3O|Mh|ryP M131NHNCVkeHUh?=
EW-22 M4rocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHkU2ZKSzVyPU[uNVk3PDlizszN MlTyV2FPT0WU
BT-474 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL1TWM2OD14LkKzN{DPxE1? MlHNV2FPT0WU
BFTC-909 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTZwM{CzOFUh|ryP NH\TVnZUSU6JRWK=
NB12 NFX4VZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTZwM{mwO|Eh|ryP MlXxV2FPT0WU
D-263MG NH75[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm1TWM2OD14LkS1NVY6KM7:TR?= MUfTRW5ITVJ?
SNB75 NUfJR3h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj4TWM2OD14Lk[wNVQ{KM7:TR?= MWPTRW5ITVJ?
A704 NUT2TYxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID2N3hKSzVyPU[uOlMxPiEQvF2= MlPSV2FPT0WU
NCI-H1693 NWTWe4ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnITWM2OD14Lk[zOlA1KM7:TR?= M2r5fnNCVkeHUh?=
LN-405 M2\wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTZwN{m2O|Ih|ryP M2XqV3NCVkeHUh?=
CHL-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnWwTWM2OD14LkiwNFc6KM7:TR?= NVO1UodTW0GQR1XS
A498 NXr5e5ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTZwOEG5OlEh|ryP M4jNeXNCVkeHUh?=
TE-12 M2exfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7pR2dKSzVyPU[uPFM5OTdizszN MV\TRW5ITVJ?
TE-6 M2\PWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;NTWM2OD14LkmzNFM5KM7:TR?= M3zPbHNCVkeHUh?=
AU565 NFrpeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTZwOU[5OVch|ryP MknFV2FPT0WU
RD MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1njOGlEPTB;Nj65PFI5PCEQvF2= NIrFU|FUSU6JRWK=
SW1463 NFH1O4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\pTWM2OD15LkGxNVY5KM7:TR?= NWHnblNYW0GQR1XS
LU-99A MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfKeFBjUUN3ME23MlE1OzJ{IN88US=> MlzZV2FPT0WU
NCI-H28 NIHaXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTdwMkmyOEDPxE1? M{S4VHNCVkeHUh?=
MC-IXC NHzwSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\YTWM2OD15LkS4OVc3KM7:TR?= NVjITGtEW0GQR1XS
GP5d M{T3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXUTWM2OD15LkS4O|Y1KM7:TR?= NYqwe2tyW0GQR1XS
GB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTdwNUS4NFQh|ryP MV;TRW5ITVJ?
CAL-33 NYjLN|RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi4PHBKSzVyPUeuOlYzOzNizszN MVfTRW5ITVJ?
MSTO-211H MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDRToRKSzVyPUeuOlc{OzZizszN MlT0V2FPT0WU
TE-5 NEn2dZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEixVFFKSzVyPUeuO|k{OzRizszN NYP5TWxCW0GQR1XS
D-566MG NEDV[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;KUWlEPTB;OD6wOFQzQSEQvF2= NX3YRY42W0GQR1XS
JVM-3 NELQUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ThV2lEPTB;OD6xOVI3QCEQvF2= MlGzV2FPT0WU
T98G NXrJSGk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRThwMUiwOlch|ryP Mn72V2FPT0WU
HCC1954 M{nsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK3dHRKSzVyPUiuOFUyODRizszN M3Hkc3NCVkeHUh?=
SF126 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRThwNEW5N|Yh|ryP NGD5XnNUSU6JRWK=
LB996-RCC M3LLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO0TWM2OD16LkWzNlU4KM7:TR?= NX3nN4NLW0GQR1XS
SKG-IIIa NIPHRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PEe2lEPTB;OD62N|A3QSEQvF2= MYrTRW5ITVJ?
NCI-SNU-1 NH[yS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13EXGlEPTB;OD62OFY1OyEQvF2= MlfBV2FPT0WU
LB771-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3UfldpUUN3ME24MlY1Pjl4IN88US=> MnPHV2FPT0WU
SCC-4 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRThwNkiyNVkh|ryP Mnj4V2FPT0WU
CAMA-1 NYrKcZQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfUOXJKSzVyPUiuO|cyPDZizszN MmfOV2FPT0WU
D-502MG MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTYT256UUN3ME24Mlc5PjJ7IN88US=> MX3TRW5ITVJ?
ESS-1 MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRThwOEi3NFQh|ryP MXnTRW5ITVJ?
HEC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRThwOEm4OlYh|ryP M2jvTnNCVkeHUh?=
NB10 M4TabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTlwMEKyNlQh|ryP MnHDV2FPT0WU
8505C MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHCbmlKUUN3ME25MlA1OjN{IN88US=> MY\TRW5ITVJ?
EFO-27 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XGU2lEPTB;OT6xOlQyOiEQvF2= NWK1c4xyW0GQR1XS
HN M{\RTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e5SmlEPTB;OT6xOlYzQCEQvF2= M2j2ZXNCVkeHUh?=
DSH1 M4CyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfB[VhvUUN3ME25MlIxQDdizszN NYr2WnptW0GQR1XS
NBsusSR M2XKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\wTWM2OD17LkK3OFAzKM7:TR?= NWnURlM{W0GQR1XS
LS-123 NIHEc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDVemVKSzVyPUmuN|E4PjFizszN MWXTRW5ITVJ?
SHP-77 NEHO[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXKTWM2OD17LkO5PVM2KM7:TR?= MXLTRW5ITVJ?
ACN MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDYTWM2OD17LkWzNlc4KM7:TR?= M3XHcnNCVkeHUh?=
U251 NFjr[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTlwNkW1OFQh|ryP NWLrTI8{W0GQR1XS
A431 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTlwOECyN|gh|ryP MXvTRW5ITVJ?
5637 NIK4T|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTlwOES5PFQh|ryP MmLUV2FPT0WU
MDA-MB-157 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTlwOUK4O|gh|ryP NVLEXo5KW0GQR1XS
A101D M{nh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTlwOUm5O|Qh|ryP NEDJNVBUSU6JRWK=
YKG-1 NGCyUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DhXmlEPTB;MUCuNlAxPiEQvF2= MVzTRW5ITVJ?
LAN-6 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn31TWM2OD1zMD6yNVY1KM7:TR?= NUDjeXJOW0GQR1XS
OVCAR-5 NVjMOItbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHWUoFKSzVyPUGwMlI1OzNizszN M2DWbHNCVkeHUh?=
A549 NUfHSGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF23PJJKSzVyPUGwMlM6PzNizszN M4HqOHNCVkeHUh?=
no-11 NHfHNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPXTWM2OD1zMD60N|U{KM7:TR?= NVXa[|NbW0GQR1XS
SF539 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X0bWlEPTB;MUCuPVA1OSEQvF2= M2nFPHNCVkeHUh?=
A388 NXzYN2d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT3RYUyUUN3ME2xNU4{QDl5IN88US=> NFvybFVUSU6JRWK=
DEL MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\lTWM2OD1zMT60NlQh|ryP NWjlXoZTW0GQR1XS
SW954 M1vZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm4cFNKSzVyPUGxMlQ3PjhizszN Mn\ZV2FPT0WU
TK10 NUTnN5pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPzTWM2OD1zMT61NlcyKM7:TR?= NV;C[oZIW0GQR1XS
SW756 M{H1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\W[mlEPTB;MUGuOVI6PCEQvF2= MXzTRW5ITVJ?
PC-3 M1e2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXnSWVKSzVyPUGxMlU4PjRizszN NWjSepVKW0GQR1XS
ONS-76 NHrXPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFzLk[zOkDPxE1? NYPDZ4s4W0GQR1XS
A427 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjzTWM2OD1zMT63NFk{KM7:TR?= MWjTRW5ITVJ?
MEG-01 Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;6TWM2OD1zMT63OVA6KM7:TR?= NVXnUoFTW0GQR1XS
BB30-HNC NYfLb4dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nMcmlEPTB;MUGuO|k5OiEQvF2= M37hOHNCVkeHUh?=
NCI-H1299 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jDWWlEPTB;MUGuPFA6OyEQvF2= MlnRV2FPT0WU
GCT NWHFZnpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnkTWM2OD1zMT64NlI5KM7:TR?= NVfifmlMW0GQR1XS
D-247MG NIruVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m0ZWlEPTB;MUGuPVY3OyEQvF2= NGX2VI1USU6JRWK=
CFPAC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFzLkm3PFIh|ryP Mn:xV2FPT0WU
EKVX MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF{LkCzNVMh|ryP NFPPNFJUSU6JRWK=
CAL-51 NWXaeXVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPVTWM2OD1zMj6wO|E3KM7:TR?= MXrTRW5ITVJ?
BB49-HNC NE\JO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33YVGlEPTB;MUKuNVE4PyEQvF2= M1zpSXNCVkeHUh?=
RPMI-7951 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljTTWM2OD1zMj6xPFU1KM7:TR?= M4H6eHNCVkeHUh?=
RH-1 NIPXR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi5b2UyUUN3ME2xNk4zOTh2IN88US=> M1u4VXNCVkeHUh?=
BCPAP M2m4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PzZ2lEPTB;MUKuOFc1QSEQvF2= MVLTRW5ITVJ?
GCIY MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHzTWM2OD1zMj61NlA6KM7:TR?= MojPV2FPT0WU
KNS-81-FD NEPYeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTue4F3UUN3ME2xNk42QDZ7IN88US=> MVfTRW5ITVJ?
KYSE-140 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXMTWM2OD1zMj64OVk2KM7:TR?= NIfHbXJUSU6JRWK=
Ca-Ski MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqxZ4xKSzVyPUGyMlkxPDFizszN M{K1cHNCVkeHUh?=
TGBC1TKB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrYZ4xKSzVyPUGyMlkyOTVizszN MUjTRW5ITVJ?
HCC1187 M3OxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHix[YpKSzVyPUGzMlE6OTJizszN MVnTRW5ITVJ?
SJSA-1 MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHJTWM2OD1zMz6yN|I4KM7:TR?= MXzTRW5ITVJ?
CTV-1 NXX1Vo9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfTbWtKSzVyPUGzMlM1PSEQvF2= M3HMeHNCVkeHUh?=
WM-115 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXQeYZKSzVyPUGzMlY1QDNizszN MnHOV2FPT0WU
CHP-212 M3zibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LtSGlEPTB;MUOuPVc{QSEQvF2= MUDTRW5ITVJ?
SCC-15 NEnUU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjVTWM2OD1zMz65O|c2KM7:TR?= MkHSV2FPT0WU
BPH-1 MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHmTWM2OD1zND6xOlY1KM7:TR?= NVy2dG5rW0GQR1XS
SW780 NGXvSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF2LkWwNlUh|ryP NFvlZlVUSU6JRWK=
NCI-H2291 M4HyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fIXGlEPTB;MUSuOVg4QCEQvF2= NVvLOmZ{W0GQR1XS
JEG-3 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXKTWM2OD1zND62N|I3KM7:TR?= NITQc|VUSU6JRWK=
CAL-120 MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XCOGlEPTB;MUSuO|AzPyEQvF2= NWSxNIRvW0GQR1XS
NCI-H23 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF2Lke5PVch|ryP MXjTRW5ITVJ?
MS-1 M1PLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:2XVhPUUN3ME2xOE46PjFzIN88US=> M{PhVHNCVkeHUh?=
PC-14 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHFTWM2OD1zND65OlU1KM7:TR?= M{HGSHNCVkeHUh?=
D-283MED NX;TPZhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\VRmlEPTB;MUWuNFEyOSEQvF2= NVLi[2oyW0GQR1XS
OE19 NIO0flVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7TbmFKSzVyPUG1MlE2PDFizszN NEnpOmlUSU6JRWK=
CAS-1 NVfNOZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq4TWM2OD1zNT60NVg1KM7:TR?= MVHTRW5ITVJ?
NCI-H727 NV\K[lZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF3LkSyNlEh|ryP M4[2V3NCVkeHUh?=
SiHa NFvUR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH32U2dKSzVyPUG1Mlc2QTRizszN M4fvUnNCVkeHUh?=
BFTC-905 NY\iNWN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLrc2V5UUN3ME2xOU44Pjl2IN88US=> MVXTRW5ITVJ?
MDA-MB-453 M2jNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TieWlEPTB;MU[uNVY1OiEQvF2= MVzTRW5ITVJ?
HuP-T3 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTF4Lk[zO|Mh|ryP M4PB[XNCVkeHUh?=
SK-LU-1 NVqzTHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37LUGlEPTB;MU[uOlk2PiEQvF2= MV7TRW5ITVJ?
Detroit562 MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O3[WlEPTB;MU[uO|MyQCEQvF2= NIjVclVUSU6JRWK=
HCC1569 M3LQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fUXmlEPTB;MU[uPFM{PyEQvF2= M{Sy[3NCVkeHUh?=
SK-MES-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP5e2xKSzVyPUG2Mlg1OTlizszN MoPqV2FPT0WU
BB65-RCC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ZNmlEPTB;MUeuNFQ4QSEQvF2= MlLJV2FPT0WU
LOXIMVI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jwPWlEPTB;MUeuNFcxPyEQvF2= NFv6V2JUSU6JRWK=
SW1783 M{K0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF5LkGyPEDPxE1? MV;TRW5ITVJ?
NH-12 NYnLU3RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTXV4NFUUN3ME2xO{4{OzB|IN88US=> NWfvflFHW0GQR1XS
UACC-257 NH6wbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKzTWM2OD1zNz61OVEzKM7:TR?= NUXLfHlRW0GQR1XS
KOSC-2 NGTCUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvTUFh4UUN3ME2xO{43PzV5IN88US=> NVLmVJF5W0GQR1XS
KG-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\kTWM2OD1zNz62PVM4KM7:TR?= MXXTRW5ITVJ?
M059J NHy0SnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHje|BKSzVyPUG3MlcxOyEQvF2= MWrTRW5ITVJ?
MHH-NB-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTGSnVlUUN3ME2xO{46Pjd|IN88US=> NUPZPXE{W0GQR1XS
EW-1 NYX1WXdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHhWohKSzVyPUG4MlE{QDJizszN MoLmV2FPT0WU
CAL-85-1 NFf5XpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF6LkKzOVch|ryP M3nhOnNCVkeHUh?=
639-V NGO4SFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXkN4JKSzVyPUG4MlM{PTRizszN M4DWWXNCVkeHUh?=
C32 M1G3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF6LkS3Nlch|ryP NXfsO4JPW0GQR1XS
KM-H2 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;rTWM2OD1zOD61NlMzKM7:TR?= M172RXNCVkeHUh?=
A253 NXrrVmd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF6LkeyPFYh|ryP NXXnd41PW0GQR1XS
NCI-N87 M4LUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC5TWM2OD1zOD65NFA5KM7:TR?= MUnTRW5ITVJ?
8-MG-BA M{W0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfuVWhKSzVyPUG5MlA3PDZizszN M4q0cHNCVkeHUh?=
GI-ME-N NX;hT5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHDPGpKSzVyPUG5MlE2PDZizszN M{jUSXNCVkeHUh?=
8305C M3f2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33WemlEPTB;MUmuNlI5PiEQvF2= M{ezXnNCVkeHUh?=
TE-8 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3QTWM2OD1zOT6zNFI1KM7:TR?= M4myOnNCVkeHUh?=
KYSE-270 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\tSGlEPTB;MkCuNFIyPyEQvF2= MlPZV2FPT0WU
HL-60 NVzXeohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHNTWM2OD1{MD6wPVQyKM7:TR?= NVXhbpZHW0GQR1XS
Mo-T NX62WnR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJyLkG2OlUh|ryP NGrnV41USU6JRWK=
NCI-H1355 NUKwdXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJyLkOzO|Qh|ryP Moj0V2FPT0WU
HT-1080 M3rFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:1VFJLUUN3ME2yNE42PDl5IN88US=> M3j6TXNCVkeHUh?=
MIA-PaCa-2 NETXRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO3TWM2OD1{MD62PFg{KM7:TR?= MnvSV2FPT0WU
NCI-H441 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHJVJFKSzVyPUKwMlc{PzlizszN MmDSV2FPT0WU
LCLC-97TM1 NH30UJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjQUYlKSzVyPUKwMlgyOzRizszN NIKzXI5USU6JRWK=
HT-3 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fOVmlEPTB;MkGuOVY{OSEQvF2= NXWwTVVOW0GQR1XS
22RV1 NXfKNIdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfETWM2OD1{MT61Olg2KM7:TR?= M{jw[3NCVkeHUh?=
LK-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnKUnZKSzVyPUKxMlU6PTNizszN NXTzNmkzW0GQR1XS
CW-2 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW5PYZrUUN3ME2yNU43ODZ7IN88US=> M3vrN3NCVkeHUh?=
KYSE-510 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfETWxKUUN3ME2yNU43ODl3IN88US=> M3;pRnNCVkeHUh?=
CGTH-W-1 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPYTGNKSzVyPUKxMlcyPjZizszN NYfUPId1W0GQR1XS
NCI-H661 NEL6fHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ{LkCzOEDPxE1? MXrTRW5ITVJ?
KU-19-19 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJ{LkG2PVch|ryP NH\TSnpUSU6JRWK=
NCI-H2122 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{eyV2lEPTB;MkKuNlQ{OiEQvF2= NEm3N2VUSU6JRWK=
NCI-H526 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW3TWM2OD1{Mj6zPFk2KM7:TR?= MVLTRW5ITVJ?
NCI-H1650 M2fwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ZOmlEPTB;MkKuO|Y1KM7:TR?= MlzXV2FPT0WU
AM-38 NGiyVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXsdW5KSzVyPUKyMlg3QDlizszN MljYV2FPT0WU
NCI-H2405 NFjFblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\lTWM2OD1{Mz6yOVM{KM7:TR?= M1PobXNCVkeHUh?=
M14 NXrRUY5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3QWpVKSzVyPUKzMlQxQDhizszN MkS1V2FPT0WU
ES4 M4WyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnhR4tDUUN3ME2yN{41OjN{IN88US=> M2jsXnNCVkeHUh?=
DJM-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrqTWM2OD1{Mz61NlM1KM7:TR?= M4TPWXNCVkeHUh?=
S-117 NYfDZ3IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuwTWM2OD1{Mz63OlUyKM7:TR?= NHTvWINUSU6JRWK=
MZ2-MEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWxbFAyUUN3ME2yN{44PzV7IN88US=> NI\1NGdUSU6JRWK=
SK-MEL-2 NXe2TZN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzrRlVZUUN3ME2yN{45OTN|IN88US=> MmjDV2FPT0WU
HCC1806 M3rxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[1RXNtUUN3ME2yN{45PzB7IN88US=> Mn60V2FPT0WU
NMC-G1 NUL5ZoxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr1ToE4UUN3ME2yOE4zOjJ4IN88US=> MXjTRW5ITVJ?
DK-MG NXLs[mMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTsTWM2OD1{ND6yPVQh|ryP MWTTRW5ITVJ?
SK-N-FI MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\p[ml1UUN3ME2yOE4{OzB{IN88US=> NVXFXWt[W0GQR1XS
KINGS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrxc2xKSzVyPUK0MlQ5PzRizszN NIXlWm9USU6JRWK=
HCC2998 M{i3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO0RXpiUUN3ME2yOE41QDh3IN88US=> NGTsN41USU6JRWK=
ALL-PO MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ2Lk[xPUDPxE1? NYHodlA6W0GQR1XS
MPP-89 NX;HeoFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ3LkC0OVgh|ryP M1zGcHNCVkeHUh?=
NCI-H2342 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnBNGdGUUN3ME2yOU4yQTV|IN88US=> MUXTRW5ITVJ?
TE-1 M4\Qd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfqfXJKSzVyPUK1MlM2PjNizszN NVSyfmFPW0GQR1XS
RH-18 Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fHOGlEPTB;MkWuOVkyQCEQvF2= MmS2V2FPT0WU
HT-1376 NH30T4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS2c4lKSzVyPUK1MlY1PjVizszN NIT4V3JUSU6JRWK=
U-2-OS Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyzfGFTUUN3ME2yOU43QDh6IN88US=> M4LXRXNCVkeHUh?=
BT-549 M{jxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ3LkmwNVEh|ryP M{PQPXNCVkeHUh?=
NCI-H1755 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG1TWM2OD1{NT65PVQ2KM7:TR?= M3vHb3NCVkeHUh?=
EW-13 M{TNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknhTWM2OD1{Nj6wNlc1KM7:TR?= NH;hfYlUSU6JRWK=
NB13 NH;JeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfQb|lLUUN3ME2yOk4xQTR7IN88US=> MmfqV2FPT0WU
NUGC-3 NXLyNIdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLEW|BjUUN3ME2yOk4zOTB|IN88US=> MonIV2FPT0WU
GMS-10 NEPBPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ4LkKzOVMh|ryP MVrTRW5ITVJ?
CHP-134 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHKOIJwUUN3ME2yOk4{QDZ5IN88US=> NF:zV2ZUSU6JRWK=
SW962 NEDNbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX1TWM2OD1{Nj61NFIyKM7:TR?= MlLXV2FPT0WU
SNU-449 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e0fWlEPTB;MkeuNFgxOyEQvF2= MWrTRW5ITVJ?
HuP-T4 NVu1WYo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH6T5FKSzVyPUK3MlA5PzlizszN MVrTRW5ITVJ?
SW948 NVrTbpBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmzbIVKSzVyPUK3MlE{PDRizszN NVTG[Zc1W0GQR1XS
NCI-H226 NFjqOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ5LkS1O|gh|ryP NE\YdVRUSU6JRWK=
SK-PN-DW M37hTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL6RXZMUUN3ME2yO{43ODF{IN88US=> NEXqS4hUSU6JRWK=
GI-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT6TWM2OD1{Nz63NlEh|ryP NEL1TXlUSU6JRWK=
CAL-12T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHiNG5KSzVyPUK4MlEyOTJizszN M{j3ZXNCVkeHUh?=
YAPC NUnjNnFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T3VWlEPTB;MkiuNlU3PCEQvF2= M4XrUXNCVkeHUh?=
SNU-C2B NWrMcI1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrqTWM2OD1{OD6yPVY1KM7:TR?= NX63V21{W0GQR1XS
RCC10RGB NFjCVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ6LkW0NVch|ryP Ml3vV2FPT0WU
ES7 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDrTWM2OD1{OT6xOFY2KM7:TR?= NGDSd2ZUSU6JRWK=
PANC-03-27 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP3fJpKSzVyPUK5MlQ1PCEQvF2= MXXTRW5ITVJ?
ES6 M2Tt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\PTWM2OD1{OT64NVU4KM7:TR?= M1vjPXNCVkeHUh?=
HT-1197 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf0fJJKSzVyPUOwMlA2QThizszN NXLkNmtSW0GQR1XS
ZR-75-30 NW\jT3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNyLkKzPFMh|ryP M1jZfXNCVkeHUh?=
DB M4O3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrhTWM2OD1|MD60PVQzKM7:TR?= NWLpPIVNW0GQR1XS
OCI-AML2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTNzLkC2PUDPxE1? MkPzV2FPT0WU
NCI-H2170 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNzLki1NVYh|ryP M1XRRXNCVkeHUh?=
IST-MES1 NVmzSldtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HDW2lEPTB;M{KuNlg6PyEQvF2= NUHxVFhMW0GQR1XS
769-P Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXG[Wt4UUN3ME2zNk4{PjRzIN88US=> MWjTRW5ITVJ?
COR-L23 NIXlSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v6PGlEPTB;M{KuPVA4OyEQvF2= NHLZ[FJUSU6JRWK=
SW626 NIrEWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy4bVZ7UUN3ME2zN{4yPzd4IN88US=> NFLNS|lUSU6JRWK=
LU-139 NEniOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTN|Lk[2NFUh|ryP M1nxbXNCVkeHUh?=
HT-144 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrkVJpJUUN3ME2zN{45PjNizszN NHi2UnRUSU6JRWK=
CaR-1 NGrrdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;5PGlEPTB;M{OuPVgzOiEQvF2= M3\hO3NCVkeHUh?=
OE33 M2jRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\PcIxpUUN3ME2zOE4zQDV3IN88US=> M1XzPHNCVkeHUh?=
COLO-800 NEfIeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjzW3VnUUN3ME2zOE4{PjR5IN88US=> NGTiWmJUSU6JRWK=
NB14 NVT1Tm9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTN2LkS2PFQh|ryP NYLoS5h7W0GQR1XS
KURAMOCHI NHvBdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN4LkGxPVgh|ryP MnfUV2FPT0WU
SW48 NGHKOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofKTWM2OD1|Nj6yOFc1KM7:TR?= M4\TSXNCVkeHUh?=
Daoy MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxU4JKSzVyPUO2MlY2OzhizszN M1vDV3NCVkeHUh?=
TGBC24TKB NWrSZVZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;sSWlEPTB;M{[uOlch|ryP MXTTRW5ITVJ?
DU-4475 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TwUWlEPTB;M{[uPVA{OyEQvF2= MmLZV2FPT0WU
SW1417 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\Te4t2UUN3ME2zPE4xPTV{IN88US=> NYnxfYNMW0GQR1XS
EFO-21 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfMUFZmUUN3ME2zPE46OzR7IN88US=> NHjORY1USU6JRWK=
MG-63 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W3VWlEPTB;M{muN|QzPCEQvF2= M2mw[3NCVkeHUh?=
LC-2-ad M2jyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrCfG5mUUN3ME2zPU42PTF{IN88US=> NHHTc2hUSU6JRWK=
NOMO-1 M17Memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\EN3hKSzVyPUO5MlgzPzRizszN NXzTWm5lW0GQR1XS
COLO-741 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnLSpZSUUN3ME20NE4yOzB2IN88US=> MmXpV2FPT0WU
BxPC-3 NUiwbldET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O3UmlEPTB;NECuOVY5PiEQvF2= MVPTRW5ITVJ?
HSC-2 NVf5dWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;CW3dKSzVyPUSwMlkyOTNizszN MX3TRW5ITVJ?
UMC-11 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\YN3N2UUN3ME20NU4zPjNizszN NHv5NWlUSU6JRWK=
HCC1937 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILvVZRKSzVyPUSyMlc5PDNizszN NGnmUI9USU6JRWK=
Calu-6 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OyfmlEPTB;NEOuNlM5OiEQvF2= NU\oNGZGW0GQR1XS
NCI-H1573 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\YVmlEPTB;NEOuN|Q4PyEQvF2= Mo\5V2FPT0WU
SK-N-AS MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO4SHFWUUN3ME20N{43ODF7IN88US=> MVrTRW5ITVJ?
PSN1 M1rxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\iRXNKSzVyPUS1MlI2PDhizszN M13kVHNCVkeHUh?=
TE-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR3LkS4OFIh|ryP MWfTRW5ITVJ?
NCI-H1155 M3GyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17pWmlEPTB;NEWuPFk3PyEQvF2= MnyxV2FPT0WU
KM12 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTR3LkmwO|Yh|ryP NYrkd3lbW0GQR1XS
RO82-W-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC2XZN4UUN3ME20Ok46QDJ{IN88US=> M1uxWnNCVkeHUh?=
SW1573 NHi5dZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OyTWlEPTB;NEeuN|c{PiEQvF2= NFLKcnVUSU6JRWK=
CAKI-1 M4DnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GyOWlEPTB;NEiuNlg1PSEQvF2= NV2yR3dFW0GQR1XS
U-118-MG M4fLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[3TWM2OD12OD6zO|AzKM7:TR?= MnLFV2FPT0WU
KYSE-520 NVqzN|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPCTWM2OD12OD60NFE3KM7:TR?= MlfMV2FPT0WU
HT55 NYrlb4dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILweHNKSzVyPUS5MlE1PzRizszN M2fBVnNCVkeHUh?=
ChaGo-K-1 M1HRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Gyd2lEPTB;NEmuOFc6OyEQvF2= MnzWV2FPT0WU
IA-LM MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfqNnRKSzVyPUW0MlY{OjJizszN NFHLV4lUSU6JRWK=
UACC-62 NIjxU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny2TWM2OD13NT6xNFQ3KM7:TR?= NFfCWYhUSU6JRWK=
MKN7 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTV4LkCyPFUh|ryP MWDTRW5ITVJ?
HPAF-II NHnvWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnu[4N6UUN3ME21Ok41ODd|IN88US=> NFLmSJNUSU6JRWK=
NTERA-S-cl-D1 NIDSNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe1coFnUUN3ME21O{44PzhizszN NIjmfoNUSU6JRWK=
FTC-133 M{XUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWezNnR6UUN3ME21PE4xQTZ7IN88US=> M2TNSnNCVkeHUh?=
MHH-ES-1 M1HQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHoTWM2OD13OD60PFE1KM7:TR?= MkG5V2FPT0WU
JVM-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfYTWM2OD13OD65OVA3KM7:TR?= NWrrR3IxW0GQR1XS
TCCSUP M{O4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13tSGlEPTB;NUmuOVI4QSEQvF2= NETpfoNUSU6JRWK=
COLO-824 NVnQSlZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DVXGlEPTB;NkCuNFcyQSEQvF2= NUXFXIw5W0GQR1XS
647-V NYXiVVAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TlW2lEPTB;NkCuNVM1PyEQvF2= M32zVHNCVkeHUh?=
HD-MY-Z M4XI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDNNVRGUUN3ME22NE42Ojl2IN88US=> NXS1VYdtW0GQR1XS
LS-411N NHLCTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOy[HJKSzVyPU[xMlM6ODNizszN M4\QN3NCVkeHUh?=
NCI-H596 M3jLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\uUFJKSzVyPU[yMlc1QTZizszN NVS3XlJQW0GQR1XS
C-33-A NELNS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnJTWM2OD14ND6wPVU4KM7:TR?= M4LxeHNCVkeHUh?=
BHY Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\FNWVKSzVyPU[0MlEzPDVizszN M{i1T3NCVkeHUh?=
KGN NFXX[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZ2LkW1NVQh|ryP M3PKfXNCVkeHUh?=
NCI-H1092 MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTZ3LkCwPVUh|ryP M3vGbnNCVkeHUh?=
MZ1-PC NFHCfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj6bo5oUUN3ME22OU42PjR7IN88US=> M{HVSHNCVkeHUh?=
LB831-BLC NEXJOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjpXoVKSzVyPU[1Mlg1QDFizszN M2XBeXNCVkeHUh?=
SW620 NEW0UZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTZ4LkKwN|kh|ryP MW\TRW5ITVJ?
HuO-3N1 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PqPWlEPTB;NkiuN|I{QCEQvF2= NED0dotUSU6JRWK=
SK-HEP-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTZ7Lkm0PFYh|ryP MmjIV2FPT0WU
LCLC-103H MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTdyLk[3NFUh|ryP MXXTRW5ITVJ?
KYSE-70 M3[0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTdyLke4N|Uh|ryP NH3rcoNUSU6JRWK=
Mewo MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXkTWM2OD15MT61NFUh|ryP M1HvUnNCVkeHUh?=
COLO-668 NHjhVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPNVIlKSzVyPUexMlg1PTFizszN NUXtTmtqW0GQR1XS
NCI-H522 M3nTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojTTWM2OD15Mj6zOFE{KM7:TR?= MmH3V2FPT0WU
NCI-H1437 NW[2RmVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrMTWM2OD15ND60NFQ5KM7:TR?= M3PBfHNCVkeHUh?=
U-266 MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOxV5hoUUN3ME23OU41PTF4IN88US=> M{nF[XNCVkeHUh?=
MC116 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHHWHFKSzVyPUe1MlU4ODhizszN NYr6enR2W0GQR1XS
PANC-10-05 NILLSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT4fHhKSzVyPUe3MlQzPDNizszN NInnbGJUSU6JRWK=
KYSE-180 NX;6S4l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i1dmlEPTB;N{euOVQ2PCEQvF2= Mo\WV2FPT0WU
JAR NVrRSW1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\6TWM2OD15OT6wOVQ3KM7:TR?= NYjhXZRMW0GQR1XS
CAL-62 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PReGlEPTB;OECuNFk2KM7:TR?= NVLuNZVTW0GQR1XS
A3-KAW MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1voNmlEPTB;OECuNlE2PCEQvF2= MVTTRW5ITVJ?
PANC-08-13 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHKTWM2OD16MT6xO|Y5KM7:TR?= NXvKXI9{W0GQR1XS
HSC-3 NEX5dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzKTWM2OD16Mz6zNFcyKM7:TR?= M3ju[nNCVkeHUh?=
HTC-C3 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jtW2lEPTB;OEOuOFcxOiEQvF2= M3TxN3NCVkeHUh?=
KY821 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTh2LkC4PVIh|ryP NIXZcGlUSU6JRWK=
DoTc2-4510 NGq5XGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq4fnJKSzVyPUi0MlIyQDVizszN MmHFV2FPT0WU
NCI-H1581 NHPTRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HLd2lEPTB;OEWuOFY1OSEQvF2= NHPCN3JUSU6JRWK=
KARPAS-299 NUDPXWcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MneyTWM2OD16Nj6xPVc4KM7:TR?= NUC4ToV2W0GQR1XS
IST-MEL1 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTh4Lki4O|Ih|ryP NXz3OVl3W0GQR1XS
KP-N-YS MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i2TmlEPTB;OEmuPVAzQCEQvF2= M2PBTnNCVkeHUh?=
KYSE-410 NVn4WoQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfncpdKSzVyPUmxMlQxPDJizszN NX2xW2NuW0GQR1XS
TE-10 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTlzLkW2NVEh|ryP MknVV2FPT0WU
SK-MEL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzPNYYzUUN3ME25Nk46OTB4IN88US=> NGLV[GRUSU6JRWK=
COLO-792 NF\kSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;mTWM2OD17NT6yOVY1KM7:TR?= NFjzUY5USU6JRWK=
SCH Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LwRmlEPTB;OU[uN|g4PyEQvF2= MWPTRW5ITVJ?
NCI-H1792 NH3UO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDaTWM2OD17Nj64PVkzKM7:TR?= NHzmS5ZUSU6JRWK=
NCI-H2029 M3OwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3KTWM2OD17Nj65OVY3KM7:TR?= M2O0NHNCVkeHUh?=
SW684 M4\rbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXSfWl5UUN3ME25PE43PjV2IN88US=> M12wOXNCVkeHUh?=
NCI-H209 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDrN|BKSzVyPUGwNE4yOjFizszN MYHTRW5ITVJ?
HLE M3r4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XH[GlEPTB;MUC1MlI5OiEQvF2= NEDMO5hUSU6JRWK=
GOTO NFf3VHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTEVoRKSzVyPUGwO{44PzdizszN M4fYU3NCVkeHUh?=
NCI-H1793 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjGT243UUN3ME2xNFkvOjhizszN MoTnV2FPT0WU
D-392MG M1zvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DHWmlEPTB;MUG3MlM6QCEQvF2= MV3TRW5ITVJ?
SW1990 NYrBR|VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jrOWlEPTB;MUKwMlk2OSEQvF2= MVzTRW5ITVJ?
ML-2 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\UTWM2OD1zMkGuOlc3KM7:TR?= NVvRelVwW0GQR1XS
NCI-H2452 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7XTWM2OD1zMkKuNlEh|ryP NF\NdnJUSU6JRWK=
SK-MEL-30 NWSxT2o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XOcGlEPTB;MUKzMlI1PCEQvF2= M1f1d3NCVkeHUh?=
SN12C MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrtTWM2OD1zMkSuNVc3KM7:TR?= MkfTV2FPT0WU
NCI-H1770 M3PCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;QTWlEPTB;MUK1MlUyPCEQvF2= NI\Re3dUSU6JRWK=
SF268 NF7vPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF{Nj6xOVgh|ryP M1XUXHNCVkeHUh?=
BALL-1 NVTaN5MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO2RXBKSzVyPUGyOk4zOyEQvF2= MVfTRW5ITVJ?
COLO-679 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF{Nj63OVMh|ryP M{HrdnNCVkeHUh?=
A2780 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF{OD65PFgh|ryP MlvuV2FPT0WU
NCI-H1651 MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPXO3VVUUN3ME2xN|EvOjR|IN88US=> MVjTRW5ITVJ?
NCI-H2087 M{n5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHLOJc2UUN3ME2xN|EvPDh|IN88US=> NVjHT3V1W0GQR1XS
U-87-MG M1T3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF|Mz62NFQh|ryP MlnuV2FPT0WU
LB2518-MEL MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ztSWlEPTB;MUO1Mlk6OyEQvF2= NI\LW|RUSU6JRWK=
HCT-116 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF|Nz6yNVch|ryP M2rk[HNCVkeHUh?=
Ca9-22 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm2XotKSzVyPUGzPU45OzNizszN M1HDNHNCVkeHUh?=
COR-L88 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj5R2dKSzVyPUG0Nk4yPCEQvF2= NHPReY1USU6JRWK=
CP50-MEL-B M1LMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[zTWM2OD1zNESuOVAyKM7:TR?= NVjLNod5W0GQR1XS
OVCAR-8 NUjBRmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT5TWM2OD1zNEWuOlM3KM7:TR?= MUfTRW5ITVJ?
SK-MEL-3 NUjIU5VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\wTWM2OD1zNEeuPFc5KM7:TR?= NW\aeIh{W0GQR1XS
GT3TKB MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfNVZZKSzVyPUG0PU46OjhizszN M{\1dnNCVkeHUh?=
KYSE-450 M4fyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17GTGlEPTB;MUWxMlU{QSEQvF2= MX;TRW5ITVJ?
CAPAN-1 NIC0eWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHWTWM2OD1zNUOuNFY1KM7:TR?= MnTaV2FPT0WU
BEN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF3Mz65Nlgh|ryP NVHHeXJlW0GQR1XS
NCI-H1304 NGfmZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT6[WdkUUN3ME2xOVQvPjl2IN88US=> MUnTRW5ITVJ?
KU812 NY\TTlM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrOTWM2OD1zNUiuOlc1KM7:TR?= Mm[yV2FPT0WU
Capan-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\hTWM2OD1zNkCuOVU{KM7:TR?= NH:0[oJUSU6JRWK=
A673 M2fVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCzTWM2OD1zNkGuO|A2KM7:TR?= M3KweHNCVkeHUh?=
SAS M1P3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PhXmlEPTB;MU[yMlY4QCEQvF2= NIDZRXFUSU6JRWK=
NY MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\lWmlEPTB;MU[1MlMyPCEQvF2= NHXGb3lUSU6JRWK=
HCE-4 NVXUUVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi4bIpKSzVyPUG2Ok45PDVizszN MVjTRW5ITVJ?
MDA-MB-231 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPPTWM2OD1zN{euOVA{KM7:TR?= MXXTRW5ITVJ?
no-10 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPnTWM2OD1zN{iuNVM1KM7:TR?= NIr0eldUSU6JRWK=
MZ7-mel M3;zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Sxd2lEPTB;MUe4MlQ3PyEQvF2= M{S3[3NCVkeHUh?=
NCI-H82 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK3TWM2OD1zOECuNVY2KM7:TR?= NIS0[pFUSU6JRWK=
CAL-72 NGT2cIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L6NWlEPTB;MUi1MlA2PCEQvF2= NX\YclNzW0GQR1XS
NCI-SNU-5 NIjwcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF6Nj64OEDPxE1? NEeze|NUSU6JRWK=
OVCAR-4 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfuOGxKSzVyPUG4PE4{OzNizszN MmThV2FPT0WU
SCC-9 M3vWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLhTWM2OD1zOUGg{txO M1G1R3NCVkeHUh?=
KYSE-150 MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF7MT64PFgh|ryP M4DQNXNCVkeHUh?=
HT-29 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Kc3pmUUN3ME2yNFEvOjF{IN88US=> MmO5V2FPT0WU
COLO-678 M1yxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGyS4lNUUN3ME2yNFEvPDVizszN NILYWVNUSU6JRWK=
NCI-H650 NXTqRpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHWTlhKSzVyPUKwNk4yODNizszN NGHGdlBUSU6JRWK=
HuCCT1 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLPTWM2OD1{MESuNlA5KM7:TR?= MWnTRW5ITVJ?
SW1116 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWftS4FKUUN3ME2yNFcvODd5IN88US=> M1;UfHNCVkeHUh?=
DBTRG-05MG MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP6VYc4UUN3ME2yNFcvQTB7IN88US=> MX\TRW5ITVJ?
SW982 NU\4XlVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{SxPGlEPTB;MkC3Mlk1QCEQvF2= MWTTRW5ITVJ?
RCM-1 NWD6UJIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXzTWM2OD1{MUSuO|YzKM7:TR?= NV7wOVFWW0GQR1XS
COLO-320-HSR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH5TWM2OD1{MU[uNVI2KM7:TR?= NUjCOVdCW0GQR1XS
KNS-42 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnncpJKSzVyPUKxOk42PzRizszN MkewV2FPT0WU
C2BBe1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ|MT65NFUh|ryP NXHxUIlOW0GQR1XS
CCRF-CEM M1H6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJ2Mz63PVUh|ryP MUPTRW5ITVJ?
SH-4 Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHLR25KSzVyPUK0Ok4xQSEQvF2= NFzXc2NUSU6JRWK=
LS-1034 NH;ZZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LabGlEPTB;MkS2MlI3PiEQvF2= MUjTRW5ITVJ?
NCI-H2347 NH7J[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ2Nz63NVMh|ryP MX\TRW5ITVJ?
RPMI-8866 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv2TWM2OD1{NEmuNlch|ryP M1K5N3NCVkeHUh?=
GAK MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXnUWZxUUN3ME2yOVMvODB{IN88US=> MVvTRW5ITVJ?
NB6 M4\OWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLxTWM2OD1{N{CuNUDPxE1? NILZUVNUSU6JRWK=
COLO-680N NV3wcVM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\X[ppKSzVyPUK3Nk42OjdizszN NHz2bXFUSU6JRWK=
RERF-LC-MS NW\zSZFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r5TmlEPTB;Mke2MlAxPyEQvF2= MnXmV2FPT0WU
TGBC11TKB NES5VVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq5XopLUUN3ME2yO|gvOTd6IN88US=> M{HSRnNCVkeHUh?=
C8166 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7UTYwxUUN3ME2yO|gvPTB4IN88US=> NWHPb3lNW0GQR1XS
HDLM-2 NGDFbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ7ND60NFkh|ryP M{XrNnNCVkeHUh?=
IGR-1 MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PIemlEPTB;Mkm1MlY2QSEQvF2= M4DDd3NCVkeHUh?=
FADU MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjtTWM2OD1{OUeuOVEh|ryP MXvTRW5ITVJ?
L-428 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zYXmlEPTB;Mkm3MlYyPiEQvF2= Mm\IV2FPT0WU
LU-65 NFy2[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TvdmlEPTB;M{C0MlMzKM7:TR?= NHfFdYtUSU6JRWK=
HEL NX6xcG5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLsVnhJUUN3ME2zNFkvQTh|IN88US=> MlX4V2FPT0WU
NCI-H810 NIjy[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES3[WFKSzVyPUOxNE42PyEQvF2= MUTTRW5ITVJ?
C3A MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHFTWM2OD1|MUGuPFAzKM7:TR?= MlLOV2FPT0WU
NCI-H630 M3;4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPjTWM2OD1|M{KuNlk1KM7:TR?= MoPzV2FPT0WU
KP-N-YN MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjNVpZwUUN3ME2zOFEvOTJ|IN88US=> NHPJXIVUSU6JRWK=
MOLT-13 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\UTWM2OD1|NEKuN|I3KM7:TR?= MUPTRW5ITVJ?
NCI-H1993 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXztfJZbUUN3ME2zOFIvOzZ3IN88US=> M331fHNCVkeHUh?=
BE-13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml70TWM2OD1|NESuNVY4KM7:TR?= MXXTRW5ITVJ?
IST-SL1 NWm5cpJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi0TWM2OD1|NEeuOFAyKM7:TR?= NEXRbY9USU6JRWK=
TE-9 NVXJ[YZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN4Mz61PFkh|ryP M2LuTnNCVkeHUh?=
LU-135 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3faV2lEPTB;M{[3MlA{PSEQvF2= MkHYV2FPT0WU
T84 NVX3T40zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jheGlEPTB;M{e0MlcyOiEQvF2= NYHReXFlW0GQR1XS
K-562 NX;jeXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PWd2lEPTB;M{izMlM3KM7:TR?= MX3TRW5ITVJ?
SBC-5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjZOotiUUN3ME2zPFYvQTh3IN88US=> MlLOV2FPT0WU
NB17 M4\RS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPxdo9UUUN3ME2zPVIvPTl4IN88US=> NIfKWJNUSU6JRWK=
NCI-H2052 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTN7OD60O|Ih|ryP MkXNV2FPT0WU
HCC38 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yyVGlEPTB;NECxMlU6OyEQvF2= MWHTRW5ITVJ?
NCI-H69 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTR2MT6wPFMh|ryP M1y3NXNCVkeHUh?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-AKT(T308) / p-AKT(S473) / pGSK3β(S9) / pFOXO1 / pPRAS(T246) / pBAD / pS6K(T389) / p4E-BP1; 

PubMed: 22932669     


ZR75-1 cells were treated with MK-2206 150 nmol/L and collected after indicated hours. Akt signaling was assessed by Western blotting. 

22932669
Growth inhibition assay
Cell viability; 

PubMed: 24665203     


(A) MK-2206 reduced the viability of anaplastic thyroid carcinoma (ATC) cells. CAL62 and KAT4 cells were treated with MK-2206 for 72 hours, followed by measurement with a cell viability assay. (B) In vitro cell viability assay of combination with MK-2206 and tyrphostin AG 1296 in KAT4 cells. 

24665203
Immunofluorescence
LC3; 

PubMed: 24490764     


Immunofluorescence staining of LC3A (green) and DAPI (blue) in M368 cells following treatment with either MK-2206, Carboplatin and Paclitaxel or the combination of all three agents for 72h.

CFTR/LC3; 

PubMed: 28794469     


Co-localisation of CFTR (red- 549nm) and LC3 (green- 488nm) in ΔF508 CFBE41o- cells treated with MK-2206 and a negative control CFBE41o- cells at 37 ℃. Nuclei were stained with DAPI (blue- 358nm). Scale bar is 10 µm.

HMGA2; 

PubMed: 24476133     


Immunofluorescent staining for HMGA2 of leiomyoma cells in control and MK-2206-treated cells was done. Cells were costained with DAPI. Immunointensity of HMGA2 expression was measured and calculated. *, P < .05; **, P < .01; ***, P < .001.

24490764 28794469 24476133
ELISA
VEGFA; 

PubMed: 29449553     


VEGF-A protein expression of conditioned medium was determined by ELISA in cervical cancer cells. The results were analyzed using one-way ANOVA. Column, mean (n = 3); bars, SD. **P < 0.01, compared with control. ##P < 0.01, compared with NF90.

29449553
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
15% Captisol
For best results, use promptly after mixing. 		17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01802320 Active not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01802320 Active not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01783171 Completed Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 15 2013 Phase 1
NCT01776008 Terminated Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 : AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) : Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products4

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • Capivasertib (AZD5363)

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID